152 related articles for article (PubMed ID: 24291501)
1. P1 and P1' para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease.
Yedidi RS; Liu Z; Kovari IA; Woster PM; Kovari LC
J Mol Graph Model; 2014 Feb; 47():18-24. PubMed ID: 24291501
[TBL] [Abstract][Full Text] [Related]
2. Crystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: mechanism of drug recognition and resistance.
Liu Z; Yedidi RS; Wang Y; Dewdney TG; Reiter SJ; Brunzelle JS; Kovari IA; Kovari LC
Biochem Biophys Res Commun; 2013 Jul; 437(2):199-204. PubMed ID: 23792096
[TBL] [Abstract][Full Text] [Related]
3. Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
Dewdney TG; Wang Y; Liu Z; Sharma SK; Reiter SJ; Brunzelle JS; Kovari IA; Woster PM; Kovari LC
Bioorg Med Chem; 2013 Dec; 21(23):7430-4. PubMed ID: 24128815
[TBL] [Abstract][Full Text] [Related]
4. A multi-drug resistant HIV-1 protease is resistant to the dimerization inhibitory activity of TLF-PafF.
Yedidi RS; Proteasa G; Martin PD; Liu Z; Vickrey JF; Kovari IA; Kovari LC
J Mol Graph Model; 2014 Sep; 53():105-111. PubMed ID: 25108107
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and evaluation of a potent substrate analog inhibitor identified by scanning Ala/Phe mutagenesis, mimicking substrate co-evolution, against multidrug-resistant HIV-1 protease.
Yedidi RS; Muhuhi JM; Liu Z; Bencze KZ; Koupparis K; O'Connor CE; Kovari IA; Spaller MR; Kovari LC
Biochem Biophys Res Commun; 2013 Sep; 438(4):703-8. PubMed ID: 23921229
[TBL] [Abstract][Full Text] [Related]
6. Crystal structures of multidrug-resistant HIV-1 protease in complex with two potent anti-malarial compounds.
Yedidi RS; Liu Z; Wang Y; Brunzelle JS; Kovari IA; Woster PM; Kovari LC; Gupta D
Biochem Biophys Res Commun; 2012 May; 421(3):413-7. PubMed ID: 22469467
[TBL] [Abstract][Full Text] [Related]
7. Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.
Liu X; Xiu Z; Hao C
J Comput Aided Mol Des; 2009 May; 23(5):261-72. PubMed ID: 19219633
[TBL] [Abstract][Full Text] [Related]
8. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
[TBL] [Abstract][Full Text] [Related]
9. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.
Logsdon BC; Vickrey JF; Martin P; Proteasa G; Koepke JI; Terlecky SR; Wawrzak Z; Winters MA; Merigan TC; Kovari LC
J Virol; 2004 Mar; 78(6):3123-32. PubMed ID: 14990731
[TBL] [Abstract][Full Text] [Related]
10. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
[TBL] [Abstract][Full Text] [Related]
11. Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir.
Sasková KG; Kozísek M; Lepsík M; Brynda J; Rezácová P; Václavíková J; Kagan RM; Machala L; Konvalinka J
Protein Sci; 2008 Sep; 17(9):1555-64. PubMed ID: 18560011
[TBL] [Abstract][Full Text] [Related]
12. A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
Amano M; Salcedo-Gómez PM; Zhao R; Yedidi RS; Das D; Bulut H; Delino NS; Sheri VR; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7046-7059. PubMed ID: 27620483
[TBL] [Abstract][Full Text] [Related]
13. The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.
Patel M; Kaltenbach RF; Nugiel DA; McHugh RJ; Jadhav PK; Bacheler LT; Cordova BC; Klabe RM; Erickson-Viitanen S; Garber S; Reid C; Seitz SP
Bioorg Med Chem Lett; 1998 May; 8(9):1077-82. PubMed ID: 9871711
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.
Reddy GS; Ali A; Nalam MN; Anjum SG; Cao H; Nathans RS; Schiffer CA; Rana TM
J Med Chem; 2007 Sep; 50(18):4316-28. PubMed ID: 17696512
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
Tie Y; Boross PI; Wang YF; Gaddis L; Liu F; Chen X; Tozser J; Harrison RW; Weber IT
FEBS J; 2005 Oct; 272(20):5265-77. PubMed ID: 16218957
[TBL] [Abstract][Full Text] [Related]
16. An in silico pharmacological approach toward the discovery of potent inhibitors to combat drug resistance HIV-1 protease variants.
Nayak C; Chandra I; Singh SK
J Cell Biochem; 2019 Jun; 120(6):9063-9081. PubMed ID: 30506751
[TBL] [Abstract][Full Text] [Related]
17. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
[TBL] [Abstract][Full Text] [Related]
18. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
[TBL] [Abstract][Full Text] [Related]
19. Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors.
Nugiel DA; Jacobs K; Kaltenbach RF; Worley T; Patel M; Meyer DT; Jadhav PK; De Lucca GV; Smyser TE; Klabe RM; Bacheler LT; Rayner MM; Seitz SP
J Med Chem; 1996 May; 39(11):2156-69. PubMed ID: 8667359
[TBL] [Abstract][Full Text] [Related]
20. A symmetric inhibitor binds HIV-1 protease asymmetrically.
Dreyer GB; Boehm JC; Chenera B; DesJarlais RL; Hassell AM; Meek TD; Tomaszek TA; Lewis M
Biochemistry; 1993 Jan; 32(3):937-47. PubMed ID: 8422397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
